Description
The ProbeSeq Glial Fibrillary Acidic Protein (GFAP) Aptamer is a high-affinity single-stranded DNA (ssDNA) molecular recognition element engineered for selective binding to human GFAP, an intermediate filament protein released following astrocyte injury. This product supports research-use biosensing and diagnostic assay development applications, including traumatic brain injury (TBI) biomarker detection, neuroinflammation studies, and integration into rapid neurological diagnostic platforms.
GFAP is a structural protein expressed primarily in astrocytes within the central nervous system and is widely recognized as a sensitive biomarker of astroglial damage. Elevated GFAP levels are associated with traumatic brain injury, stroke, neurodegeneration, and blood–brain barrier disruption. Sensitive detection of GFAP is critical for neurotrauma research, disease monitoring studies, and development of rapid point-of-care neurological testing technologies.
This aptamer provides selective molecular recognition of GFAP through sequence-defined binding interactions that support high target specificity and strong binding affinity under physiologically relevant conditions. Compared with antibody-based recognition elements, aptamers offer improved chemical stability, reproducible synthesis, and compatibility with electrochemical sensing platforms, surface functionalization strategies, and microfluidic diagnostic systems.
The aptamer sequence is optimized to minimize non-specific interactions, support stable surface immobilization, and maintain binding performance across diverse assay environments, enabling reliable integration into biosensor development workflows and translational research platforms.
This product supports research programs focused on neurological diagnostics, biosensor engineering, and advanced neuroinjury biomarker detection technologies.
What’s Included
Each product contains:
-
High-affinity ssDNA aptamer targeting human GFAP
-
Sequence documentation for research traceability
-
Reconstitution guidelines and handling instructions
Custom sequence modifications and bulk quantities are available upon request.
Target Strategy
The aptamer is selected against human GFAP to support:
-
High binding specificity to astroglial GFAP protein
-
Minimal cross-reactivity with unrelated cytoskeletal proteins
-
Stable performance under physiological buffer conditions
-
Compatibility with biosensor surface immobilization strategies
Target selection prioritizes sensitivity and integration into diagnostic and sensing platforms.
Product Format
Available in two configurations:
Lyophilized format
• Delivered dry for enhanced stability
• Reconstitute in nuclease-free water or preferred buffer
Solution format
• Supplied at defined stock concentration (e.g., 100 µM)
• Provided in nuclease-free water or TE buffer
Custom concentrations and modification options available upon request.
Performance Orientation
Designed for compatibility with:
-
Electrochemical biosensors
-
Optical and fluorescence-based detection systems
-
Surface immobilization platforms
-
Microfluidic and lab-on-chip systems
-
Point-of-care neurodiagnostic device development
-
Rapid assay prototyping workflows
Quality Control
Each batch undergoes:
-
Sequence verification
-
Purity confirmation (HPLC purification)
-
Concentration validation
-
Manufacturing quality control review
Certificate of Analysis (CoA) available upon request.
Applications
-
Traumatic brain injury biomarker detection research
-
Neuroinflammation and neurodegeneration studies
-
Stroke biomarker research
-
Biosensor development and validation
-
Neurological diagnostic assay development
-
Microfluidic and point-of-care platform integration
Storage
Store at –20 °C.
Lyophilized aptamers are stable for up to 12 months. Avoid repeated freeze–thaw cycles for solution format.
